Brian W. Loggie, MD CM, FRCSC, FACS
Brian W. Loggie, MD, CM, FRCSC, FACS, grew up in Montreal, Canada, and earned a Bachelor of Science degree from Montreal’s Loyal College. He received his Medical Degree from McGill University in 1979. From 1979-86, Dr. Loggie completed an internship and surgical residency at the Department of Surgery, Montreal General Hospital, Montreal, Canada. Concurrently with his residency, he completed graduate studies in the Department of Experimental Surgery, McGill University, Montreal, Canada, from 1982-86.
Dr. Loggie has held faculty positions at University of Illinois at Chicago, Chicago, IL, 1986-88, Bowman Gray School of Medicine, Winston-Salem, NC, 1988-2000, University of Texas Southwestern Medical Center, Dallas, TX 2000-2002 and Creighton University School of Medicine, Omaha, NE, 2002-present. At Creighton University, he serves as a Professor of Surgery and Chief in the Division of Surgical Oncology and Director of the Cancer Center at Creighton University Medical Center. In 2007, he was named holder of The Dr. Harold J. Bonnstetter Endowed Chair in Preventive Medicine at Creighton University School of Medicine.
Dr. Loggie’s expertise is in surgical oncology and the management and treatment of rare cancers, including peritoneal mesothelioma, cutaneous malignant melanoma, peritoneal carcinomatosis and malignant ascites, abdominopelvic and retroperitoneal sarcomas, pseudomyxoma peritonei, and management of complex primary or recurrent solid tumors. He also has an interest in peritoneal neoplastic disease, appendix neoplasms, gastrointestinal cancers, and ovarian cancer. His research interests also include Cox 2 mucinous cancers, estrogen receptor regulation and clinical trials for mesothelioma.
Before coming to the Creighton University School of Medicine, Dr. Loggie worked at Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, where he pioneered the use of heated chemotherapy and cytoreductive surgery for the treatment of peritoneal cancer. His research has led him to support the new and existing mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor as predictors of the optimal resectability in Mesothelioma.